Related Experiment Video

Updated: May 9, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

[Advances on effects of triptolide with non-small cell lung cancer]

Li Wang1, Yong Song

  • 1Department of Respiratory Medicine, Nanjing General Hospital of Nanjing Command, Clinical School of the Medical College of Nanjing University, Nanjing 210002, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|July 23, 2013
PubMed

Insights

Triptolide effectively targets non-small cell lung cancer by disrupting cell cycles and activating cell death pathways. This natural compound shows promise for lung cancer treatment research and clinical applications.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Context:

  • Non-small cell lung cancer (NSCLC) remains a significant health challenge.
  • Triptolide is a compound with demonstrated anti-cancer properties.

Purpose:

  • To summarize the anti-tumor mechanisms and effects of triptolide in non-small cell lung cancer.
  • To provide insights for future research and clinical applications.

Summary:

  • Triptolide exhibits anti-cancer activity against various non-small cell lung cancer cell lines.
  • It functions by interfering with the cell cycle and activating caspase signaling pathways.
  • Triptolide inhibits vascular endothelial growth factor (VEGF) expression and nuclear factor-kappa B (NF-κB) activation, promoting cancer cell apoptosis.

Impact:

  • This summary aids scientific research into triptolide's anti-cancer mechanisms.
  • It offers potential therapeutic strategies for non-small cell lung cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...